The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate

Vaccine

Volumn 27, Issue 21, 2009, Pages 2816-2822

  Yu, Yun Zhou ^a   Li, Na ^a   Zhu, Heng Qi ^a   Wang, Rui Lin ^a   Du, Yun ^a   Wang, Shuang ^a   Yu, Wei Yuan ^a   Sun, Zhi Wei ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

Botulism; Clostridium botulinum; Neurotoxin; Recombinant AHc; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; BOTULINUM TOXIN; POLYHISTIDINE TAG; RECOMBINANT HC DOMAIN NEUROTOXIN A; RESIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BOTULISM; CARBOXY TERMINAL SEQUENCE; CHROMATOGRAPHY; CLOSTRIDIUM BOTULINUM; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG FORMULATION; ESCHERICHIA COLI; FEMALE; HEAVY CHAIN; HYDROPHOBICITY; ION EXCHANGE; ION EXCHANGE CHROMATOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SERODIAGNOSIS; SEROTYPE; SURVIVAL; VACCINATION;

ANIMALS; BACTERIAL VACCINES; BOTULINUM TOXIN TYPE A; BOTULISM; CLOSTRIDIUM BOTULINUM; ESCHERICHIA COLI; FEMALE; MICE; MICE, INBRED BALB C; PEPTIDES, CYCLIC; PROTEIN SUBUNITS; RECOMBINANT PROTEINS;

EID: 64449088954     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.091     Document Type: Article

References (28)

1. Schiavo G., Matteoli M., and Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 80 (2000) 717-766
2. Turton K., Chaddock J.A., and Acharya K.R. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci 27 (2002) 552-558
3. Byrne M.P., and Smith L.A. Development of vaccines for prevention of botulism. Biochimie 82 (2000) 955-966
4. Middlebrook J.L. Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology. Adv Drug Deliv Rev 57 (2005) 1415-1423
5. Smith L.A., and Rusnak J.M. Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol 27 (2007) 303-318
6. Yu Y.Z., Sun Z.W., Wang S., and Yu W.Y. High-level expression of the Hc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli and its immunogenicity as an antigen. Chin J Biotech 23 (2007) 812-817
7. Yu Y.Z., Sun Z.W., Li N., Wang S., Wang R.L., and Yu W.Y. Protection with a recombinant Hc of Clostridium botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine. Immunopharmacol Immunotoxicol (2008) 10.1080/08923970802438433
8. Yu Y.Z., Zhang S.M., Sun Z.W., Wang S., and Yu W.Y. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. Vaccine 25 (2007) 8843-8850
9. Clayton M.A., Clayton J.M., Brown D.R., and Middlebrook J.L. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun 63 (1995) 2728-2742
10. LaPenotiere H.F., Clayton M.A., and Middlebrook J.L. Expression of a large nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen. Toxicon 33 (1995) 1383-1386
11. Holley J.L., Elmore M., Mauchline M., Minton N., Titball R.W., and Cloning. expression and evaluation sub-unit vaccine against clostridium type F toxin. Vaccine 19 (2001) 288-297
12. Woodward L.A., Arimitsu H., Hirst R., and Oguma K. Expression of Hc subunits from Clostridium botulinum type C and D and their evaluation as candidate vaccine antigens in mice. Infect Immun 71 (2003) 2941-2944
13. Byrne M.P., Smith T.J., Montgomery V.A., and Smith L.A. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 66 (1998) 4817-4822
14. Potter K.J., Bevins M.A., Vassilieva E.V., Chiruvolu V.R., Smith T., Smith L.A., et al. Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype B, expressed in the methyltrophic yeast Pichia pastoris. Protein Expr Purif 13 (1998) 357-365
15. Smith L.A. Development of recombinant vaccines for botulinum toxin. Toxicon 36 (1998) 1539-1548
16. Byrne M.F., Titball R.W., Holley J., and Smith L.A. Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris. Protein Expr Purif 18 (2000) 327-337
17. Boles J., West M., Montgomery V., Tammariello R., Pitt M.L., Gibbs P., et al. Recombinant C fragment of botulinum neurotoxin serotype B (rBoNTB(Hc)) immune response and protection in the rhesus monkey. Toxicon 47 (2006) 877-884
18. Dux M.P., Barent R., Sinha J., Gouthro M., Swanson T., Barthuli A., et al. Purification and scale-up of a recombinant heavy chain fragment C of botulinum neurotoxin serotype E in Pichia pastoris GS115. Protein Expr Purif 45 (2006) 359-367
19. Potter K.J., Zhang W., Smith L.A., and Meagher M.M. Production and purification of the heavy chain fragment C of the botulinum neurotoxin, serotype A, expressed in the methyltrophic yeast Pichia pastoris. Protein Expr Purif 19 (2000) 393-402
20. Webb R.P., Smith T.J., Wright P.M., Montgomery V.A., Meagher M.M., and Smith L.A. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine 25 (2007) 4273-4282
21. Gurkan C., and Ellar D.J. Recombinant production of bacterial toxins and their derivatives in the methylotrophic yeast Pichia pastoris. Microb Cell Fact 4 (2005) 33
22. Tavallaie M., Chenal A., Gillet D., Pereira Y., Manich M., Gibert M., et al. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett 572 (2004) 299-306
23. Baldwin M.R., Tepp W.H., Pier C.L., Bradshaw M., Ho M., Wilson B.A., et al. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect Immun 73 (2005) 6998-7005
24. Lee J.C., Hwang H.J., Sakaguchi Y., Yamamoto Y., Arimitsu H., Tsuji T., et al. C terminal half fragment (50 kDa) of heavy chain components of Clostridium botulinum C and D neurotoxins can be used as an effective vaccine. Microbiol Immunol 51 (2007) 445-455
25. Ravichandran E., Al-Saleem F.H., Ancharski D.M., Elias M.D., Singh A.K., Shamim M., et al. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 75 (2007) 3043-3054
26. Baldwin M.R., Tepp W.H., Przedpelskil A., Pier C.L., Bradshaw M., Johnson E.A., et al. A subunit vaccine against the seven serotypes of botulism. Infect Immun 76 (2008) 1314-1318
27. Lindblad E.B. Aluminum adjuvants-in retrospect and prospect. Vaccine 22 (2004) 3658-3668
28. Yu Y.Z., Li N., Wang R.L., Zhu H.Q., Wang S., Yu W.Y., et al. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Clin Vaccine Immunol 15 (2008) 1819-1823